Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed the day trading at $16.61 down -2.41% from the previous closing price of $17.02. In other words, the price has decreased by -$2.41 from its previous closing price. On the day, 0.84 million shares were traded. CNTA stock price reached its highest trading level at $16.93 during the session, while it also had its lowest trading level at $16.46.
Ratios:
For a better understanding of CNTA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.37 and its Current Ratio is at 14.37. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on July 21, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On May 28, 2025, Needham started tracking the stock assigning a Buy rating and target price of $35.
On May 08, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $30.Chardan Capital Markets initiated its Buy rating on May 08, 2025, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 29 ’25 when Accardi Mario Alberto sold 8,322 shares for $15.23 per share. The transaction valued at 126,751 led to the insider holds 208,163 shares of the business.
Accardi Mario Alberto bought 8,322 shares of CNTA for $127,909 on Jul 29 ’25. On Jul 25 ’25, another insider, Weinhoff Gregory M, who serves as the Chief Business Officer of the company, sold 10,000 shares for $15.56 each. As a result, the insider received 155,598 and left with 122,279 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 2219411712 and an Enterprise Value of 2052898816. For the stock, the TTM Price-to-Sale (P/S) ratio is 147.31 while its Price-to-Book (P/B) ratio in mrq is 5.74. Its current Enterprise Value per Revenue stands at 136.86 whereas that against EBITDA is -10.505.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.49, which has changed by 0.5086285 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $19.09, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 15.74%, while the 200-Day Moving Average is calculated to be 9.40%.
Shares Statistics:
Over the past 3-months, CNTA traded about 1.05M shares per day on average, while over the past 10 days, CNTA traded about 1375640 shares per day. A total of 133.55M shares are outstanding, with a floating share count of 85.48M. Insiders hold about 36.00% of the company’s shares, while institutions hold 57.34% stake in the company. Shares short for CNTA as of 1752537600 were 3674823 with a Short Ratio of 3.48, compared to 1749772800 on 4468784. Therefore, it implies a Short% of Shares Outstanding of 3674823 and a Short% of Float of 3.2399999999999998.
Earnings Estimates
The market rating of Centessa Pharmaceuticals plc ADR (CNTA) is currently shaped by the ongoing analysis conducted by 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.31 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.22 and -$1.5 for the fiscal current year, implying an average EPS of -$1.33. EPS for the following year is -$1.58, with 7.0 analysts recommending between -$1.34 and -$1.81.
